Detecting Disease Before It Happens
Most patients think of cardiovascular risk in terms of cholesterol. They’ve been told their LDL is “good” or “a little high,” and they assume that number defines their risk.
The problem is that cholesterol, as it is typically measured, is an incomplete and often misleading marker.
At our clinic in Boise, one of the most common scenarios we see is a patient with “normal” cholesterol who, upon further evaluation, is already developing atherosclerosis. This disconnect exists because traditional lipid panels do not capture the full picture.
Cardiovascular disease is not simply a function of how much cholesterol is circulating. It is a function of how many atherogenic particles are present, how those particles interact with the arterial wall, and the metabolic environment in which they exist.
This is where markers like ApoB become more useful.
ApoB represents the number of atherogenic particles—LDL, VLDL, and others—that have the potential to penetrate the arterial wall and initiate plaque formation. Multiple studies have demonstrated that ApoB correlates more strongly with cardiovascular events than LDL-C alone.
Two patients can have identical LDL levels but very different ApoB levels. The patient with higher ApoB has more particles, and therefore higher risk.
We incorporate ApoB as a foundational component of cardiovascular risk assessment.
Another critical marker is Lp(a), a genetically determined lipoprotein associated with increased cardiovascular risk. Elevated Lp(a) is present in approximately 20% of the population and is often not identified in standard care.
What makes Lp(a) important is that it is:
- Independent of traditional risk factors
- Largely genetically determined
- Associated with early and aggressive atherosclerosis
Identifying elevated Lp(a) changes how aggressively we approach risk reduction.
At some point, however, lab data needs to be correlated with actual disease.
This is where imaging becomes essential.
Coronary artery calcium (CAC) scoring provides a direct measure of calcified plaque within the coronary arteries. It is one of the most validated tools in preventive cardiology and significantly improves risk stratification beyond traditional models.
For more detailed assessment, coronary CT angiography (CCTA) allows visualization of both calcified and non-calcified plaque. This is particularly important because non-calcified, or “soft,” plaque is more prone to rupture and cause acute events.
These tools shift the conversation from theoretical risk to actual disease burden.
Another key component is metabolic health. Cardiovascular disease is not simply a lipid disorder—it is heavily influenced by insulin resistance, inflammation, and body composition. Patients with elevated visceral fat and poor metabolic health are more likely to develop and progress atherosclerosis.
This is why we integrate:
👉 DEXA scans in Boise
👉 VO2 max testing in Boise
into our cardiovascular assessments.
The goal is not just to identify risk, but to understand the underlying physiology driving that risk.
Once identified, intervention becomes targeted. This may include lifestyle changes, omega-3 optimization, or pharmacologic therapy when appropriate. The focus is always on reducing actual event risk—not just improving lab numbers.
The most important shift is moving from reactive care to proactive detection.
Patients do not develop heart disease overnight. It is a process that unfolds over years. The earlier it is identified, the more effectively it can be managed.
Bottom line: cardiovascular disease is largely preventable, but only if it is detected early and approached with precision.